Search Result

Results for "

NAMPT+inhibitor

" in MedChemExpress (MCE) Product Catalog:

By Targets:	AMPK (1) Apoptosis (6) Autophagy (2) Cytochrome P450 (1) DNA Alkylator/Crosslinker (1) DNA/RNA Synthesis (2) Drug Intermediate (1) Drug-Linker Conjugates for ADC (6) GLUT (1) Isocitrate Dehydrogenase (IDH) (1) mTOR (1) NAMPT (31) PAK (1) PARP (2) PROTACs (2) Quinone Reductase (1) Reactive Oxygen Species (ROS) (1) Reference Standards (1) TMV (1)
By Research Areas:	Cancer (36) Infection (1) Inflammation/Immunology (1) Metabolic Disease (2) Neurological Disease (2)
Click Chemistry:	Alkynes (1)

Inhibitors & Agonists

Click Chemistry

Cat. No.	Product Name	Target	Research Areas	Chemical Structure

HY-147193

Nampt-IN-10 TFA	NAMPT	Cancer
Nampt-IN-10 TFA (compound 4) is a Nicotinamide Phosphoribosyltransferase *(NAMPT)* inhibitor. Nampt-IN-10 TFA shows cellular potency to A2780 and CORL23 cells lines with IC₅₀s of 5 and 19 nM, respectively. Nampt-IN-10 TFA can be used as a novel non-antimitotic payload for ADCs .

HY-12793

Padnarsertib 3 Publications Verification KPT-9274	PAK NAMPT	Cancer
Padnarsertib (KPT-9274) is an orally bioavailable, dual PAK4/Nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with IC₅₀s of <100 nM and 120 nM, respectively .

HY-18728

STF-31 Maximum Cited Publications 17 Publications Verification	GLUT Autophagy	Cancer
STF-31 is a selective inhibitor of glucose transporter 1 (GLUT1), with an IC₅₀ of 1 μM. STF-31 is also a *NAMPT* inhibitor. STF-31 inhibits glucose uptake in renal cell carcinoma (RCC) 4 cells .

HY-15766

GNE-617 5+ Cited Publications	NAMPT	Metabolic Disease Cancer
GNE-617 is a specific *NAMPT* inhibitor that inhibits the biochemical activity of NAMPT with an IC₅₀ of 5 nM and exhibits efficacy in xenograft models of cancer.

HY-112615

NAMPT inhibitor-linker 1	Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 1 is a agent-linker conjugates for ADC, composed of an *NAMPT* inhibitor as a payload, and a linker. ADC-3 consists of an NAMPT inhibitor-linker 1 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526 cells, with IC₅₀s of <3 pM and 9 pM, respectively.

HY-12808

STF-118804 2 Publications Verification	NAMPT AMPK mTOR	Cancer
STF-118804 is a highly specific *NAMPT* inhibitor. STF-118804 activates AMPK and inhibits mTOR pathways. STF-118804 has antitumor activity against pancreatic cancer .

HY-402237

Nampt-IN-15	NAMPT	Neurological Disease Cancer
Nampt-IN-15 (Example 3) is an *Nampt* inhibitor. Nampt-IN-15 shows cytotoxicity against BxPC-3, HepG2, L540cy and MOLM-13, with IC₅₀s of 38.5 nM, 8 nM, 8.5 nM, 7 nM respectively .

HY-112616

NAMPT inhibitor-linker 2	NAMPT Drug-Linker Conjugates for ADC	Cancer
NAMPT inhibitor-linker 2 is a agent-linker conjugates for ADC, composed of an *NAMPT* inhibitor as a payload, and a linker. ADC-4 consists of an NAMPT inhibitor-linker 2 and an anti-c-Kit monoclonal antibody, exihibits potent activity against c-Kit expressing cell lines such as GIST-T1 and NCI-H526, with IC₅₀s of <7 pM and 40 pM, respectively.

HY-12971

Nampt-IN-1 2 Publications Verification LSN3154567	NAMPT	Cancer
Nampt-IN-1 (LSN3154567) is a potent and selective *NAMPT* inhibitor. Nampt-IN-1 inhibits purified NAMPT with an IC₅₀ of 3.1 nM.

HY-12628

GNE-618 2 Publications Verification	NAMPT	Cancer
GNE-618 is a potent, orally active nicotinamide phosphoribosyl transferase (NAMPT) inhibitor with an IC₅₀ of 6 nM. GNE-618 depletes NAD levels and induces tumor cell death. Anti-tumor activity .

HY-14373

CB30865 ZM 242421	NAMPT	Cancer
CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC₅₀ values in the 1-10 nM range) . CB30865 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

HY-14374

GPP78 CAY10618	NAMPT Autophagy	Inflammation/Immunology Cancer
GPP78 (CAY10618) is a potent *Nampt* inhibitor with an IC₅₀ of 3.0 nM for nicotinamide adenine dinucleotide (NAD) depletion. GPP78 is cytotoxic to neuroblastoma cell line SH-SY5Y cells with an IC₅₀ of 3.8 nM by inducing autophagy. GPP78 has anti-cancer and anti-inflammatory effects .

HY-W017463

trans-3-(3-Pyridyl)acrylic acid	Drug Intermediate TMV Isocitrate Dehydrogenase (IDH)	Infection
trans-3-(3-Pyridyl) acrylic acid is an unsaturated carboxylic acid and synthetic building block, which serves as a synthetic precursor of 3-(3-pyridyl) propanoic acid. trans-3-(3-Pyridyl) acrylic acid can be used to prepare dual mutant *IDH1/NAMPT** inhibitors* and PGE₂ antagonist analogs. In addition, trans-3-(3-Pyridyl) acrylic acid exhibits antiviral activity against tobacco mosaic virus (TMV) .

HY-147193A

Nampt-IN-10 trihydrochloride	NAMPT	Cancer
Nampt-IN-10 trihydrochloride (compound 4) is a Nicotinamide Phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-10 trihydrochloride shows cellular potency to A2780 and CORL23 cell lines with IC₅₀ values of 5 and 19 nM, respectively. Nampt-IN-10 trihydrochloride can be used as a novel non-antimitotic payload for antibody-drug conjugate (ADC) .

HY-125147

A-1293201	NAMPT	Cancer
A-1293201 is a substrate-independent NAMPT inhibitor with antitumor activity. A-1293201 effectively reduces the total cellular NAD ⁺/NADH (NADt) level, subsequently leading to ATP depletion and cancer cell death. In addition, A-1293201 can effectively overcome the acquired resistance mechanism of the NAMPT Y18 mutant to CHS-828 (HY-10079) .

HY-164759

Nampt-IN-13	NAMPT	Cancer
Nampt-IN-13 (example 58m) is a *NAMPT* inhibitor that can be used in the synthesis of Antibody-drug Conjugate (ADC) .

HY-15766A

GNE-617 hydrochloride 5+ Cited Publications	NAMPT	Cancer
GNE-617 hydrochloride is a specific *NAMPT* inhibitor that inhibits the biochemical activity of NAMPT with an IC₅₀ of 5 nM and exhibits efficacy in xenograft models of cancer.

HY-164705

Mal-Toxophore	Drug-Linker Conjugates for ADC	Cancer
Mal-Toxophore is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164759) .

HY-147838

Nampt-IN-9	NAMPT	Cancer
Nampt-IN-9 (Compound 8) is a potent *NAMPT* inhibitor with anticancer activities. Nampt-IN-9 can be used for pancreatic ductal adenocarcinoma research .

HY-15766R

GNE-617 (Standard)	NAMPT	Metabolic Disease Cancer
GNE-617 (Standard) is the analytical standard of GNE-617. This product is intended for research and analytical applications. GNE-617 is a specific NAMPT inhibitor that inhibits the biochemical activity of NAMPT with an IC50 of 5 nM and exhibits efficacy in xenograft models of cancer.

HY-130606

Nampt-IN-5	NAMPT Cytochrome P450	Cancer
Nampt-IN-5 is a potent nicotinamide phosphoribosyltransferase (NAMPT) inhibitor. Nampt-IN-5 also inhibits CYP3A4 activity and has cellular IC₅₀s of 0.7 nM and 3.9 nM against A2780 and COR-L23, respectively .

HY-161180

Antitumor agent-136	NAMPT	Cancer
Antitumor Agent-136 (Compound 17) is a potent broad-spectrum antitumor agent and a *NAMPT* inhibitor with an IC₅₀ of 9.5 nM. Antitumor Agent-136 can reduce the levels of intracellular and extracellular *NAMPT* protein through the ubiquitin proteasome pathway, thus achieving tumor inhibition .

HY-162537

LYP-8	PROTACs NAMPT	Cancer
LYP-8 is a potent and effective *NAMPT* degrader with maximum degradation of 97% at 0.5 μM in SKOV-3 cells. LYP-8 shows anti-cancer activity in vivo and in vitro(Sturcture Note:(Blue: Cereblon ligand (HY-112078), Black: linker (HY-128801)；Pink: Nampt inhibitor Nampt-IN-11 (HY-158689)) .

HY-176237

Nampt-IN-16	NAMPT Apoptosis	Cancer
Nampt-IN-16 (Compound 9a) is an orally active *NAMPT* inhibitor with an IC₅₀ of 0.15 μM. Nampt-IN-16 can reduce intracellular NAD ⁺ and ATP levels. Nampt-IN-16 can inhibit the proliferation, migration, and invasion, induce cell cycle arrest and apoptosis, and alter cellular metabolism of gastric cancer cells. Nampt-IN-16 can be used in the research of tumors such as gastric cancer .

HY-170972

*PARP1/NAMPT-IN-2*	Apoptosis PARP NAMPT	Cancer
PARP1/NAMPT-IN-2 (Compound 13j) is a dual *PARP/NAMPT* inhibitor with IC₅₀ values of 0.8 nM and 18 nM for PARP1 and *NAMPT, respectively. PARP1/NAMPT-IN-2 can inhibit* the proliferation, migration and induce apoptosis of breast cancer cells. PARP1/NAMPT-IN-2 can be used for the research of triple-negative breast cancer .

HY-101280

LB-60-OF61	NAMPT	Cancer
LB-60-OF61 is a *NAMPT* inhibitor and is a cytotoxic compound with a selectivity towards MYC overexpressing cell lines .

HY-164707

MC7	Drug-Linker Conjugates for ADC	Cancer
MC7 is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-402237) .

HY-161051

Anticancer agent 177	NAMPT DNA Alkylator/Crosslinker	Cancer
Anticancer agent 177 (Compound 11b) is a *NAMPT* inhibitor and DNA alkylating agent. Anticancer agent 177 has antitumor activity in vitro and in vivo .

HY-164706

m-PEG6-Lys-Mal-Toxophore-quinoline	Drug-Linker Conjugates for ADC	Cancer
m-PEG6-Lys-Mal-Toxophore-quinoline is a drug-linker conjugate for ADC and can be used for ADC synthesis. The payload is a NAMPT inhibitor (HY-164760) .

HY-147795

Nampt-IN-8	Quinone Reductase NAMPT Apoptosis Reactive Oxygen Species (ROS)	Cancer
Nampt-IN-8 (Compound 10d) is an *NAMPT* inhibitor with an IC₅₀ of 0.183 μM. Nampt-IN-8 is also a relatively good NQO1 substrate. Nampt-IN-8 induces cell apoptosis and ROS .

HY-147756

Nampt-IN-7	NAMPT	Cancer
Nampt-IN-7 (compound GF8) is a potent *NAMPT* inhibitor, with an IC₅₀ of 7.31 μM. Nampt-IN-7 also displays cytotoxic activity against human HepG2 hepatocellular carcinoma cell line with an IC₅₀ of 24.28 μM .

HY-159015

SIAIS630120-NC	PROTACs	Cancer
SIAIS630120-NC is a negative control for NAMPT (nicotinamide phosphoribosyltransferase) degrader SIAIS630120 (Sturcture Note:(Blue: Cereblon ligand Thalidomide (HY-14658) analogue (HY-138793), Black: linker；Pink: Nampt inhibitor FK866 (HY-50876)) .

HY-101280R

LB-60-OF61 (Standard)	NAMPT Reference Standards	Cancer
LB-60-OF61 (Standard) is the analytical standard of LB-60-OF61 (HY-101280). This product is intended for research and analytical applications. LB-60-OF61 is a NAMPT inhibitor and is a cytotoxic compound with a selectivity towards MYC overexpressing cell lines .

HY-181863

Nampt-IN-18	NAMPT DNA/RNA Synthesis Apoptosis	Cancer
Nampt-IN-18 (Compound Q24) is an orally active *NAMPT* inhibitor with an IC₅₀ of 8.0 nM against hNAMPT. Nampt-IN-18 inhibits NAMPT enzymatic activity. Nampt-IN-18 inhibits DNA synthesis and induces Apoptosis. Nampt-IN-18 exhibits anticancer activity against gastric cancer and colorectal cancer. Nampt-IN-18 can be used for the research of gastrointestinal cancers .

HY-182567

Nampt-IN-19	NAMPT	Cancer
Nampt-IN-19 is an orally active and non-substrate nicotinamide phosphoribosyltransferase (NAMPT) inhibitor with a human K_i of 5.6 nM. Nampt-IN-19 blocks NAD ⁺ biosynthesis from Nicotinamide (HY-B0150). Nampt-IN-19 acts as an antiproliferative agent in cancer cells. Nampt-IN-19 has preclinical pharmacokinetic properties supporting oral antitumor activity in mouse xenograft models. Nampt-IN-19 can be used for the research of colorectal cancer .

HY-181911

L2-FK866	Drug-Linker Conjugates for ADC NAMPT	Neurological Disease
L2-FK866 is an ADC payload-linker conjugate (Drug-linker conjugate for ADC). L2-FK866 contains the ADC linker (Val-Cit-p-aminobenzyl) and the *NAMPT* inhibitor FK866 (HY-50876). L2-FK866 can be conjugated with Dinutuximab (HY-P9933) to form an ADC. L2-FK866 is applicable to neuroblastoma research .

HY-181578

Nampt-IN-17	NAMPT Apoptosis	Cancer
Nampt-IN-17 is an selective orally active *NAMPT* inhibitor with a human NAMPT IC₅₀ of 17 nM and K_i of 25.9 nM. Nampt-IN-17 depletes intracellular NAD ⁺ and ATP, disrupts mitochondrial membrane potential, suppresses cell proliferation, self-renewal, invasion, and migration, induces cell-cycle arrest and apoptosis. Nampt-IN-17 exhibits selective activity against NAPRT-deficient gastric cancer cells. Nampt-IN-17 can be used for the research of NAPRT-deficient gastric cancer .

HY-181254

*PARP1/NAMPT-IN-1*	PARP NAMPT DNA/RNA Synthesis Apoptosis	Cancer
PARP1/NAMPT-IN-1 is a potent and dual PARP1 and *NAMPT* inhibitor with IC₅₀ values of 1.2 nM and 6.7 nM, respectively. PARP1/NAMPT-IN-1 can disrupt the homologous recombination repair (HRR) pathway, leading to the accumulation of DNA double-strand breaks (DSBs), inducing cell cycle arrest and apoptosis, and also has antimigratory effects. PARP1/NAMPT-IN-1 exhibits excellent antitumor effects in a breast cancer xenograft model. PARP1/NAMPT-IN-1 can be used for the study of triple-negative breast cancer (TNBC) .

Cat. No.	Product Name		Classification

HY-14373

CB30865 ZM 242421		Alkynes
CB30865 (ZM 242421) is a nicotinamide phosphoribosyltransferase (Nampt) inhibitor, with potent cytotoxicity. CB30865 is highly potent against a variety of human tumour cell lines (IC₅₀ values in the 1-10 nM range) . CB30865 is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.

Inquiry Online

Your information is safe with us. * Required Fields.

MCE Japan Authorized Agent ナミキ商事株式会社コスモ・バイオ株式会社重松貿易株式会社
Salutation			Country or Region *
Applicant Name *			Organization Name *
Department *
Email Address *			Product Name *
Cat. No.			Requested quantity *
Phone Number *
Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: